Posted on 24 February 2015
Tags: big pharma, Gilead, Mylan, partnering
Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India.
As Gilead's exclusive branded medicine distribution partner, Mylan expects to begin distribution of Sovaldi in India in Q2 2015.
Searching for more deal information? Current Partnering offers the following options:
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
|
Sovaldi received regulatory approval in India in January 2015 the first country in Asia to approve the medicine.
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio
